InflaRx N.V. (IFRX) Rises to $41.91 on Apr, 6

InflaRx N.V. (NASDAQ:IFRX) rose significantly to $41.91. It was announced on Apr, 6 by Barchart.com. It has $1.09 billion MC. The company’s valuation will be $76.16M more at $44.84 target.

For more InflaRx N.V. (NASDAQ:IFRX) news brought out briefly go to: Globenewswire.com, Globenewswire.com, Seekingalpha.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum – GlobeNewswire” brought out on February 27, 2019, “InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” on February 06, 2019, “InflaRx Update: Pipeline Continues To Progress, Data In 1H 2019 – Seeking Alpha” with a publish date: November 24, 2018, “InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results – GlobeNewswire” and the last “InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shares – GlobeNewswire” with publication date: May 08, 2018.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States.The firm is worth $1.09 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases.Currently it has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

InflaRx N.V. (NASDAQ:IFRX) Analyst Ratings Chart


Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *